VKH
VRDN icon

Virtu KCG Holdings’s Viridian Therapeutics VRDN Stock Holding History

Virtu KCG Holdings’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-101
Closed -$12K – 3375
2016
Q1 		$12K Sell
101
-42
-29% -$5.37K ﹤0.01% 2640
2015
Q4 		$24K Sell
143
-58
-29% -$11.2K ﹤0.01% 3290
2015
Q3 		$42K Buy
+201
New +$70.6K ﹤0.01% 3033
2015
Q2 		– Sell
-117
Closed -$56K – 3794
2015
Q1 		$56K Buy
+117
New +$67.6K ﹤0.01% 2806

Other funds holding VRDN

HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
ICAS
Investors Capital Advisory Services Lynnfield, Massachusetts $521M AUM 1.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Virtu KCG Holdings's VRDN Position: Q2 2016 in Review

Virtu KCG Holdings sold out of Viridian Therapeutics (VRDN) in Q2 2016, closing a stake of 101 shares — an estimated $12K sold.

Virtu KCG Holdings first reported a position in VRDN in Q1 2015 and held it in 4 quarters. The position peaked at $56K in Q1 2015. 9 funds tracked by Wall St. Rank hold VRDN as of Q2 2016.

  • Virtu KCG Holdings reported no remaining Viridian Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 101 Viridian Therapeutics shares in Q2 2016, an estimated $12K.
  • Virtu KCG Holdings first reported a position in Viridian Therapeutics in Q1 2015 and held it in 4 quarters.
  • Virtu KCG Holdings's Viridian Therapeutics position peaked at $56K in Q1 2015.
  • 9 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2016.

Based on Virtu KCG Holdings's 13F filing for Q2 2016, filed 12 Aug 2016.